Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging.
Cancer-associated fibroblasts
FAPI radiotracer
Immune therapy
Metastases
Tumor microenvironment
Journal
Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
09
01
2022
revised:
09
03
2022
accepted:
24
04
2022
pubmed:
1
5
2022
medline:
23
11
2022
entrez:
30
4
2022
Statut:
ppublish
Résumé
Cancer-Associated Fibroblasts (CAFs) represent the most prominent component of the tumor microenvironment (TME). Recent studies demonstrated that CAF are heterogeneous and composed of different subpopulations exerting distinct functions in cancer. CAF populations differentially modulate various aspects of tumor growth, including cancer cell proliferation, extra-cellular matrix remodeling, metastatic dissemination, immunosuppression and resistance to treatment. Among other markers, the Fibroblast Activation Protein (FAP) led to the identification of a specific CAF subpopulation involved in metastatic spread and immunosuppression. Expression of FAP at the surface of CAF is detected in many different cancer types of poor prognosis. Thus, FAP recently appears as an appealing target for therapeutic and molecular imaging applications. In that context,
Identifiants
pubmed: 35489628
pii: S1044-579X(22)00102-X
doi: 10.1016/j.semcancer.2022.04.008
pii:
doi:
Substances chimiques
Gelatinases
EC 3.4.24.-
Serine Endopeptidases
EC 3.4.21.-
Membrane Proteins
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
262-272Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest F.M.-G. received research support from Innate-Pharma, Roche and Bristol-Myers-Squibb (BMS). A.P. declares no potential conflict of interest. F-C.B. received research support from Roche. I.B. receives research support from Siemens Healthineers, GE Healthcare and Dosisoft.